A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses

Journal of Clinical Psychopharmacology

Volumn 16, Issue 1, 1996, Pages 19-25

  Barbhaiya, Rashmi H ^a   Buch, Akshay B ^a   Greene, Douglas S ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; DEXTROMETHORPHAN; DRUG METABOLITE; HYDROXYNEFAZODONE; NEFAZODONE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; SEX DIFFERENCE; STEADY STATE;

ADOLESCENT; ADULT; AGED; AGING; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOTRANSFORMATION; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; SEX CHARACTERISTICS; TRIAZOLES;

EID: 0030023969     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199602000-00004     Document Type: Article

References (21)

1. Feighner JP, Pambakian R, Fowler RC, Boyer WF, D'Amico MF. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989;25:219-21.
2. Hyslop DK, Allen LE, Taylor DP. Triazolo antidepressants do not inhibit monoamine oxidase. Drug Dev Res 1988;12:77-89.
3. Eison AS, Eison MS, Torrente JR, Wright RN, Yucca FD. Nefa zodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-5.
4. 3a. Kaul S, Shukla UA, Barbhaiya RH. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 1995;35:830-9.
5. 3b. Barbhaiya RH, Shukla UA, Greene DS. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol (in press).
6. van Laar MW, van Willigenburg APP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995;15:30-40.
7. Buch AB, Shukla UA, Pittman K, Barbhaiya RH. Pharmacokinetics of nefazodone in extensive and poor metabolizers of dextromethorphan. Pharm Res 1993;10:S314.
8. Guttendorf RJ, Wedlund PJ, Blake J, Chang SL. Simplified phenotyping with dextromethorphan by thin-layer chromatography: application to clinical laboratory screening for deficiencies in oxidative drug metabolism. Ther Drug Monit 1988;10:490-8.
9. Franc JE, Duncan GF, Farmen RH, Pittman KA. High-performance liquid Chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr 1991;570:129-38.
10. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
11. Riegelman S, Collier P. An application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980;8:509-34.
12. Conover WJ, Iman RL, Rank transformation as a bridge between parametric and nonparametric analyses of data. Am Stat 1981;35:124-33.
13. Box GEP, Cox DR. Analysis of transformations. J R Stat Soc 1964;265(Ser B):211-52.
14. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, IA: Iowa State University Press, 1980;253-4.
15. Gill JL. Design and analysis of experiments in the animal and medical sciences. Ames, IA: The Iowa State University Press, 1978;179-82.
16. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos Biol Fate Chem 1994;22:304-11.
17. Durnas C, Loi C-M, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990;19:359-89.
18. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). Clin Pharmacokinet 1990;21:165-77.
19. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;80:60-75.
20. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991;6[suppl 2]:11-21.
21. Bergstrom RF, Lemberger L, Farid NA, Wolen RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988;153[suppl 3]:47-50.